Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 4/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.34 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8515878 | 0.89 | PIK3CD (0.35) | PIK3CAPIK3CDPIK3CBPIK3CGHDAC11 | |
| SCHEMBL8514748 | 0.88 | PIK3CD (0.36) | PIK3CAPIK3CDPIK3CBPIK3CGHDAC11 | |
| SCHEMBL8538864 | 0.88 | PIK3CD (0.36) | PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL8534844 | 0.83 | PIK3CA (0.39) | PIK3CAMTNR1BMTNR1A | |
| SCHEMBL16479935 | 0.75 | PIK3CA (0.31) | PIK3CA | |
| SCHEMBL858862 | 0.74 | CREBBP (0.34) | PIK3CA | |
| SCHEMBL3764167 | 0.73 | GPR142 (0.35) | PIK3CAPIK3CDPIK3CB | |
| SCHEMBL858672 | 0.72 | NPC1 (0.36) | PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL857756 | 0.72 | AOC3 (0.35) | PIK3CATRPV1 | |
| SCHEMBL856456 | 0.72 | PIK3CA (0.42) | PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140073628-A1 | BENZOXAZEPINES ASN INHIBITORS OF P13K/M TOR AND METHODS OF THEIR USE AND MANUFACTURE | RICE KENNETH D (US) | 2014-03-13 | — | — | US | disclosed |
| EP-2643315-A1 | BENZOXAZEPINES AS INHIBITORS OF P13K/mTOR AND METHODS OF THEIR USE AND MANUFACTURE | Exelixis, Inc. (US) | 2013-10-02 | — | — | EP | disclosed |
| WO-2012071501-A1 | BENZOXAZEPINES ASN INHIBITORS OF P13K/M TOR AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073628-A1 | BENZOXAZEPINES ASN INHIBITORS OF P13K/M TOR AND METHODS OF THEIR USE AND MANUFACTURE | MTOR, RPTOR, RICTOR | PIK3CA 12/4885PIK3CD 24/4885PIK3CB 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.